Management of Cardiac Symptoms in Amyloidosis
Authors:
- 27 February 2022
- journal article
- review article
- Published by Elsevier in The American Journal of Medicine
- Vol. 135, S9-S12
Abstract
No abstract availableKeywords
Funding Information
- Alnylam Pharmaceuticals
- Janssen Pharmaceutica
This publication has 22 references indexed in Scilit:
- Fludrocortisone Is Associated With a Higher Risk of All‐Cause Hospitalizations Compared With Midodrine in Patients With Orthostatic HypotensionJournal of the American Heart Association, 2017
- Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathyHeart Rhythm, 2016
- 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac deathEuropean Heart Journal, 2015
- Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic roleAmyloid, 2015
- Implantable Cardioverter Defibrillators in Patients with Cardiac AmyloidosisJournal of Cardiovascular Electrophysiology, 2013
- Cardiac AmyloidosisCirculation, 2012
- Prophylactic pacemaker implantation in familial amyloid polyneuropathyHeart Rhythm, 2012
- Pressure-Volume Relationships in Patients With Transthyretin (ATTR) Cardiac Amyloidosis Secondary to V122I Mutations and Wild-Type TransthyretinCirculation: Heart Failure, 2011
- Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac deathHeart Rhythm, 2008
- Intracardiac Thrombosis and Embolism in Patients With Cardiac AmyloidosisCirculation, 2007